trial

Enhancing Recovery in Early Schizophrenia

NCTId NCT02926859
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Active Not Recruiting
Enrollment 180 (estimated)
Sponsored by Central Institute of Mental Health, Mannheim
Primary completion 2027-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Active Not Recruiting
Enrollment
180 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-04-08
Primary completion
2027-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Cannabidiol

Sponsors

Central Institute of Mental Health, MannheimLead Sponsor

Investigators

1
F. Markus Leweke, MDPrincipal Investigator

Sites

6 total
Mannheim, GermanyMunich, GermanyBerlin, GermanyAachen, GermanyCologne, GermanyHamburg, Germany

Linked catalysts

1
Enhancing Recovery in Early Schizophrenia — primary completion2027-12

Facts & assertions

4 sourced
Enrollment
180
Phase
PHASE2
Primary Completion Date
2027-12
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
Cannabidiol
drug
lead_sponsor
Central Institute of Mental Health, Mannheim
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
F. Markus Leweke, MD
person